- Home
- BSX
as 11-20-2024 3:32pm EST
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
| Founded: | 1979 | Country: | United States |
| Employees: | N/A | City: | MARLBOROUGH |
| Market Cap: | 133.1B | IPO Year: | 1992 |
| Target Price: | $93.73 | AVG Volume (30 days): | 6.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 23 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.21 | EPS Growth: | 47.19 |
| 52 Week Low/High: | $53.93 - $91.08 | Next Earning Date: | 10-23-2024 |
| Revenue: | $15,911,000,000 | Revenue Growth: | 15.66% |
| Revenue Growth (this year): | 17.61% | Revenue Growth (next year): | 12.32% |
Stock Insider Trading Activity of Boston Scientific Corporation (BSX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Mahoney Michael F | BSX | Chairman, President & CEO | Nov 5 '24 | Sell | $84.96 | 162,778 | $13,794,850.92 | 1,521,205 | |
| Carruthers Wendy | BSX | EVP, Human Resources | Nov 1 '24 | Sell | $84.33 | 6,983 | $588,876.39 | 32,028 | |
| Mahoney Michael F | BSX | Chairman, President & CEO | Oct 7 '24 | Sell | $84.63 | 162,777 | $13,775,791.62 | 1,521,205 | |
| Fitzgerald Joseph Michael | BSX | EVP & Group Pres, Cardiology | Oct 7 '24 | Sell | $85.00 | 132,527 | $11,264,887.77 | 160,467 | |
| Carruthers Wendy | BSX | EVP, Human Resources | Oct 1 '24 | Sell | $83.86 | 6,983 | $585,594.38 | 32,028 | |
| Mahoney Michael F | BSX | Chairman, President & CEO | Sep 5 '24 | Sell | $81.17 | 162,777 | $13,212,543.98 | 1,521,205 | |
| Carruthers Wendy | BSX | EVP, Human Resources | Sep 3 '24 | Sell | $81.70 | 6,983 | $570,511.10 | 32,028 | |
| Fitzgerald Joseph Michael | BSX | EVP & Group Pres, Cardiology | Aug 28 '24 | Sell | $80.00 | 14,132 | $1,130,560.00 | 160,467 | |
| Butcher Arthur C | BSX | EVP& Grp Pres, MedSurg & APAC | Aug 26 '24 | Sell | $79.25 | 14,012 | $1,110,515.46 | 10,802 |
Latest Boston Scientific Corporation News
BSX Breaking Stock News: Dive into BSX Ticker-Specific Updates for Smart Investing
Insider Monkey
18 hours ago
Boston Scientific Corporation (BSX)’s Breakthroughs: A Hidden Gem in Billionaire Ken Griffin’s Portfolio
Zacks
2 days ago
Reasons to Retain BSX Stock in Your Portfolio for Now
Zacks
2 days ago
BSX Stock Gains From Positive OPTION Trial Data for WATCHMAN FLX
Zacks
2 days ago
Boston Scientific Stock Set to Gain From Completion of Axonics Deal
Yahoo Finance
3 days ago
Inside a $400 billion bet on the brain-computer interface revolution
Simply Wall St.
3 days ago
Here's Why We Think Boston Scientific (NYSE:BSX) Might Deserve Your Attention Today
Argus Research
3 days ago
Weekly Stock List
MedTech Dive
3 days ago
Boston Scientific’s Watchman could be new option for patients post ablation: study
Compare BSX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BSX Boston Scientific Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.